Kaleido Stock Financials

KLDO -  USA Stock  

USD 5.78  0.11  1.94%

Understanding current and past Kaleido Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kaleido Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Kaleido Biosciences' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Kaleido Biosciences' financials over time to get the whole picture. Kaleido Biosciences Invested Capital is quite stable at the moment as compared to the past year. The company's current value of Invested Capital is estimated at 16.41 Million. Tangible Asset Value is expected to rise to about 68.5 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (83.1 M).
Please make use of analysis of Kaleido Biosciences fundamentals to determine if markets are correctly pricing the entity. We were able to break down thirty-three available fundamentals for Kaleido Biosciences, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Kaleido Biosciences financials, including its revenue, cash flow from operations, current liabilities, as well as the relationship between the cash per share and market capitalization . Given that Kaleido Biosciences has a price to book of 3.36 X, we recommend you to check Kaleido Biosciences last-minute market performance to make sure the company can sustain itself down the road. Use Kaleido Biosciences to enhance returns of your portfolios. The stock experiences a large bullish trend. Check odds of Kaleido Biosciences to be traded at $6.36 in 90 days.

Search Fundamentals 

 
Refresh
With this module, you can analyze Kaleido financials for your investing period. You should be able to track the changes in Kaleido Biosciences individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Less than 14
Kaleido Biosciences has less than 14 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Kaleido Biosciences stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Kaleido Biosciences' official financial statements usually reflect Kaleido Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kaleido Biosciences. For example, before you start analyzing numbers published by Kaleido accountants, it's critical to develop an understanding of what Kaleido Biosciences' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kaleido Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kaleido Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kaleido Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kaleido Biosciences. Please utilize our Beneish M Score to check the likelihood of Kaleido Biosciences' management to manipulate its earnings.

Kaleido Biosciences Company Summary

Kaleido Biosciences competes with Edesa Biotech, and Dynavax Technologies. Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP483347100
LocationMassachusetts; U.S.A
Business Address65 Hayden Avenue
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitekaleido.com
Phone617 674 9000
CurrencyUSD - US Dollar

Kaleido Biosciences Key Financial Ratios

Generally speaking, Kaleido Biosciences' financial ratios allow both analysts and investors to convert raw data from Kaleido Biosciences' financial statements into concise, actionable information that can be used to evaluate the performance of Kaleido Biosciences over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Kaleido Biosciences reports annually and quarterly.

Kaleido Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kaleido Biosciences's current stock value. Our valuation model uses many indicators to compare Kaleido Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kaleido Biosciences competition to find correlations between indicators driving Kaleido Biosciences's intrinsic value. More Info.
Kaleido Biosciences is currently regarded as number one stock in earnings per share category among related companies. It is currently regarded as number one stock in z score category among related companies .

Kaleido Biosciences Systematic Risk

Kaleido Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kaleido Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Kaleido Biosciences correlated with the market. If Beta is less than 0 Kaleido Biosciences generally moves in the opposite direction as compared to the market. If Kaleido Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kaleido Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kaleido Biosciences is generally in the same direction as the market. If Beta > 1 Kaleido Biosciences moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Kaleido Biosciences Financials

What exactly are Kaleido Biosciences Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Kaleido Biosciences' income statement, its balance sheet, and the statement of cash flows. Potential Kaleido Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2018 2019 2020 2021 (projected)
Current Assets76.24 M73.28 M48.72 M58.47 M
Total Assets85.33 M82.31 M59.34 M68.54 M

Kaleido Biosciences August 4, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Kaleido Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kaleido Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kaleido Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Kaleido Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kaleido Biosciences's daily price indicators and compare them against related drivers.
Information Ratio(0.07)
Maximum Drawdown28.54
Value At Risk(8.40)
Potential Upside8.59
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.